The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma

The Aspartate aminotransaminase/Alanine aminotransaminase ratio (AST/ALT ratio) has been identified as a prognostic marker for several malignancies. In this study, we evaluated the prognostic value of the AST/ALT ratio in a large cohort of non-metastatic colorectal cancer patients (CRC). A total of...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2021-01, Vol.41 (1), p.429-436
Main Authors: Scheipner, Lukas, Smolle, Maria Anna, Barth, Dominik, Posch, Florian, Stotz, Michael, Pichler, Martin, StÖger, Herbert, Gerger, Armin, Riedl, Jakob Michael
Format: Article
Language:English
Subjects:
Aged
Alanine
Alanine Transaminase - blood
Aspartate Aminotransferases - blood
Biomarkers, Tumor
Cancer
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - blood
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - mortality
Colorectal Neoplasms - therapy
Female
Humans
Male
Markers
Metastases
Metastasis
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Proportional Hazards Models
Regression analysis
Retrospective Studies
Statistical analysis
Survival
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Aspartate aminotransaminase/Alanine aminotransaminase ratio (AST/ALT ratio) has been identified as a prognostic marker for several malignancies. In this study, we evaluated the prognostic value of the AST/ALT ratio in a large cohort of non-metastatic colorectal cancer patients (CRC). A total of 536 patients with stage II and III CRC, as well as available AST/ALT ratio were included in this single-center retrospective analysis. Laboratory data were measured within two weeks before histological tumor diagnosis. Co-Primary endpoints for this analysis were disease-free survival (DFS) and overall survival (OS). In univariate cox regression DFS was significantly shorter in patients with an elevated AST/ALT ratio (HR=1.568, 95%CI=1.10-2.23, p=0.012). In multivariable analysis, the prognostic association between an elevated AST/ALT ratio and a poor survival prevailed statistically significant (HR=1.53, 95%C=1.05-2.22, p=0.026). No statistically significant association between the AST/ALT ratio and OS was observed (HR=1.4, 95% CI=0.89-2.22, p=0.14). In this study, the serum AST/ALT ratio emerged as a valid prognostic marker for DFS in non-metastatic colorectal cancer patients at stage II and III.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.14792